Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 4—April 2023
Research

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

Aharona Glatman-FreedmanComments to Author , Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, and Michal Bromberg
Author affiliations: Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, Y. Hershkovitz, R. Dichtiar, A. Rosenberg, L. Keinan-Boker, M. Bromberg); Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Table 1

Characteristics of SARS-CoV-2 cases included in study of effectiveness of BNT162b2 vaccine against Omicron variant infection in children 5–11 years of age, January 20–February 15, 2022, Israel

Variable Cases, no. (%), n = 78,541
Age, y
5 9,783 (12.5)
6 11,310 (14.4)
7 11,529 (14.7)
8 11,599 (14.8)
9 11,468 (14.6)
10 11,562 (14.7)
11
11,290 (14.4)
Sex
F 39,175 (49.9)
M
39,366 (50.1)
Population group
Ultra-Orthodox Jews 2,194 (2.8)
General* 54,700 (69.6)
Arabs
21,647 (27.6)
Socioeconomic status
Low 26,048 (33.2)
Medium 36,515 (46.5)
High 15,978 (20.3)

*Includes non–ultra-Orthodox Jews and non-Arab minorities.

Main Article

Page created: February 08, 2023
Page updated: March 20, 2023
Page reviewed: March 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external